Table 3. Obstructive pulmonary disease and the risk of sudden cardiac arrest stratified by age group, sex and cardiovascular risk profile1.
| Outcome | Cases | Controls | Unadjusted | Adjusted OR2 (95% CI) | ||
| N = 1310 | N = 5793 | OR (95% CI) | ||||
| By age group (years) | ||||||
| <65 with OPD | 58/546 (11%) | 163/2421 (7%) | 1.6 (1.2–2.3) | 1.6 (1.2–2.3) | ||
| ≥65 with OPD | 132/764 (17%) | 459/3372 (14%) | 1.3 (1.1–1.6) | 1.3 (1.03–1.6) | ||
| By sex | ||||||
| Women with OPD | 51/295 (17%) | 124/1291 (10%) | 2.0 (1.3–2.8) | 1.8 (1.3–2.6) | ||
| Men with OPD | 139/1015 (14%) | 498/4502 (11%) | 1.3 (1.04–1.6) | 1.3 (1.03–1.6) | ||
| By cardiovascular risk-profile | ||||||
| No OPD | Low risk profile | 342 (26%) | 2505 (43%) | Reference | n/a | |
| High risk profile | 778 (59%) | 2666 (46%) | 2.5 (2.1–2.9) | n/a | ||
| OPD | Low risk profile | 39 (3%) | 239 (4%) | 1.3 (0.9–1.9) | n/a | |
| High risk profile | 151 (12%) | 383 (7%) | 3.5 (2.7–4.4)3 | n/a | ||
Data are number (%). CI: confidence interval, CVD: cardiovascular disease, N: number, n/a: not applicable, OPD: obstructive pulmonary disease, OR: odds ratio.
1
Use of β- adrenoreceptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, diuretics, angiotensin-II receptor blockers, nitrates, platelet aggregation inhibitors, and/or statins within six months prior to index date.
2
Adjusted for cardiovascular risk profile.
3
Interaction on a multiplicative scale: OR 1.1 (0.7–1.6), on an additive scale: synergy index 1.4 (0.7–2.6).